학술논문
Interferon Gamma-Induced Protein (IP-10) as Potential Biomarker for Cancer-Related-Fatigue: Results from a 6-month Randomized Controlled Trial.
Document Type
Journal Article
Author
Source
Subject
*CLINICAL trials
*INTERFERON gamma
*PROTEINS in the body
*CANCER fatigue
*COGNITIVE therapy
*BEHAVIOR therapy
*TUMOR diagnosis
*COMPARATIVE studies
*CYTOKINES
*LONGITUDINAL method
*FATIGUE (Physiology)
*RESEARCH methodology
*MEDICAL cooperation
*RESEARCH
*TIME
*TUMORS
*EVALUATION research
*RANDOMIZED controlled trials
*TREATMENT effectiveness
*PREDICTIVE tests
*CROSS-sectional method
*SEVERITY of illness index
*DISEASE complications
*DIAGNOSIS
*THERAPEUTICS
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
0735-7907
Abstract
We examined if serum concentrations Interferon gamma-induced protein (IP-10) is a potential clinical biomarker for cancer-related-fatigue (CRF). Fatigue scores and IP-10 concentrations were measured from curatively treated fatigued cancer patients randomized to either cognitive behavioral therapy (CBT, n = 26) or waiting-list (WL, n = 13). No correlation was found between baseline IP-10 level and fatigue severity and no significant differences in IP-10 serum levels were observed between fatigued and matched non-fatigued patients (n = 22). Relative changes in IP-10 concentrations from baseline to six-month follow-up were not significantly different between the CBT and WL conditions. In this study, IP-10 showed low potential as clinical CRF biomarker.Trial Registration: This study is registered at ClinicalTrials.gov (NCT01096641). [ABSTRACT FROM AUTHOR]